Why the study?
This statement was updated to enhance efficient referral from general practitioners or non-cardiovascular specialists and to provide an up-to-date perspective on BNP and NT-proBNP in heart failure diagnosis and management.
The 2023 Japanese Heart Failure Society statement updates cutoff values and management strategies for BNP and NT-proBNP in clinical practice.
Answers are grounded in this paper and cite their sources.
Adopt updated BNP/NT-proBNP cutoffs for HF diagnosis and referral; extends prior guidance on BNP-guided therapy.
This revised 2023 statement on blood brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain (B-type) natriuretic peptide (NT-proBNP) represents an expert consensus that aims to enhance efficient referral from general practitioners or non-cardiovascular specialists, providing a comprehensive, up-to-date perspective on BNP and NT-proBNP in the diagnosis and management of heart failure, with a focus on the following two major modifications: (1) Changes regarding cutoff values for BNP and NT-proBNP (criteria for heart failure diagnosis and referral criteria to cardiovascular specialists); and (2) Content related to heart failure management using BNP and NT-proBNP (BNP-guided therapy).
No takes yet. Share an insight, caveat, or question.
Minamisawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: